MedTrace Logo

Staged and Combined Surgery for Cataract Patients With Corneal Endothelial Dysfunction

NCT02523950 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-04-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of staged and combined phacoemulsification with intraocular lens implantation and Descemet membrane endothelial keratoplasty (DMEK) to treat cataract patients with corneal endothelial dysfunction. Surgical and postoperative complications, visual acuity and corneal endothelial cell density are evaluated.

Conditions

  • Cataract
  • Corneal Endothelial Keratopathy
  • Phacoemulfisication+IOL Implantation
  • Endothelial Keratopathy

Interventions

PROCEDURE

Staged phacoemulsification and DMEK

Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells. Stage 2. DMEK is performed secondarily according to the corneal status of patients.

PROCEDURE

Combined phacoemulsification and DMEK

Routine phacoemulsification and DMEK are performed simultaneously.

DEVICE

Intraocular lens (IOL) implantation

After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.

Sponsors & Collaborators

  • Haotian Lin

    lead OTHER

Principal Investigators

  • Yizhi Liu, M.D., Ph.D. · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02523950 on ClinicalTrials.gov